CoChat

Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis

Dolladille, Charles, Akroun, Julia, Morice, Pierre-Marie, Dompmartin, Anne, Ezine, Emilien, Sassier, Marion, Da-Silva, Angélique, Plane, Anne-Flore, Legallois, Damien, L’Orphelin, Jean-Mathieu, Alexandre, Joachim · 2021 · European Heart Journal
Cited by 205

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Aims: The risk and incidence of cardiovascular (CV) immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) in cancer patients remain unknown. Methods and results: We systematically reviewed all randomized clinical trials (RCTs) including at least one ICI-containing arm and available CV adverse event (CVAE) data in cancer patients in the ClinicalTrials.gov registry, Medline, and the Cochrane CENTRAL Register of Controlled Trials, up to 31 August 2020 (CRD42020165672). The primary outcome was the summary risk of 16 different CVAEs associated with ICI exposure vs. controls (placebo and non-placebo) in RCTs. CVAEs with an increased risk associated with ICI exposure were considered as CV irAEs. Summary incidences of CV irAEs identified in our primary outcome analyses were computed using all RCTs including at least one ICI-containing arm. We used a random-effects meta-analysis to obtain Peto odds ratios (ORs) with 95% confidence intervals (CIs) and logit transformation and inverse variance weighting to compute summary incidences. Sixty-three unique RCTs with at least one ICI-containing arm (32 518 patients) were retrieved, among which 48 (29 592 patients) had a control arm. Among the 16 CVAEs studied, ICI use was associated with an increased risk of 6 CV irAEs including myocarditis, pericardial diseases, heart failure, dyslipidemia, myocardial infarction, and cerebral arterial ischaemia with higher risks for myocarditis (Peto OR: 4.42, 95% CI: 1.56–12.50, P < 0.01; I 2 = 0%, P = 0.93) and dyslipidemia (Peto OR: 3.68, 95% CI: 1.89–7.19, P < 0.01; I 2 = 0%, P = 0.66). The incidence of these CVAEs ranged from 3.2 (95% CI 2.0–5.1) to 19.3 (6.7–54.1) per 1000 patients, in studies with a median follow-up ranging from 3.2 to 32.8 months. Conclusion: In RCTs, ICI use was associated with six CV irAEs, not confined to myocarditis and pericarditis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehab618

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 205

Metadata

Authors
Dolladille, C., Akroun, J., Morice, P.-M., Dompmartin, A., Ezine, E., Sassier, M., Da-Silva, A., Plane, A.-F., Legallois, D., L’Orphelin, J.-M., & Alexandre, J.
Venue
European Heart Journal
Published
2021-09-16
Volume
42
Issue
48
Pages
4964-4977
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3200806721
Cited by
205
References
8
FWCI
8.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. https://app.cochat.ai/papers/10.1093/eurheartj/ehab618
The paper
Dolladille, C., Akroun, J., Morice, P.-M., Dompmartin, A., Ezine, E., Sassier, M., Da-Silva, A., Plane, A.-F., Legallois, D., L’Orphelin, J.-M., & Alexandre, J. (2021). Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab618

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.